News >

Algazi Attests to Benefit of Continuous Dosing of BRAF/MEK Inhibitors in Melanoma

Brittany Cote
Published: Wednesday, May 06, 2020

Alain Algazi, MD, an associate professor in the Department of Medicine at University of California San Francisco

Alain Algazi, MD

Continuous dosing with the BRAF and MEK inhibitors dabrafenib (Tafinlar) and trametinib (Mekinist) resulted in superior progression-free survival (PFS) compared with intermittent dosing in patients with BRAF V600-mutated melanoma, according to Alain Algazi, MD, who added that these findings sharply contrasted with what had been observed in animal models.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication